Drug Trial Radar · NCT05118789
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
359
Planned (sponsor's estimate)
Start
Jan 4, 2022
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Nuvalent Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of zidesamtinib in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of zidesamtinib at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of zidesamtinib in patients with advanced ROS1-positive NSCLC and other solid tumors.
Conditions
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
Zidesamtinib (NVL-520)Drug
Oral tablet of zidesamtinib (NVL-520)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) (Phase 1)Time frame: Within 28 days of last patient dosed during dose escalation
- Recommended Phase 2 Dose (RP2D)Time frame: Within 28 days of last patient dosed during dose escalation.
- Objective Response Rate (ORR) (Phase 2)Time frame: 2-3 years after first patient dosed.
Locations
63 sites in 14 countries. Site status is shown where the registry gives one.
UCI Medical Center
Orange, California · Recruiting
Stanford Medicine
Palo Alto, California · Recruiting
UC Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
University of Colorado Cancer Center
Denver, Colorado · Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
University of Miami
Coral Gables, Florida · Recruiting
University of Chicago
Chicago, Illinois · Recruiting
Mass General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Cancer Institute
Detroit, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
NYU Langone Health
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Atrium Health Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
MD Anderson Cancer Center
Houston, Texas · Active not recruiting
NEXT Oncology - Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
University Hospital Leuven
Leuven, Belgium · Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
Princess Margaret Cancer Research
Toronto, Ontario, Canada · Recruiting
Centre Legon Berard
Lyon, France · Recruiting
CHU de Nantes
Nantes, France · Recruiting
Claudius Regaud Institute
Toulouse, France · Recruiting
Institute Gustave Roussy
Villejuif, France · Recruiting
Cologne University Hospital
Cologne, Germany · Recruiting
Università Politecnica Marche
Ancona, Italy · Recruiting
IRCCS Istituto Tumori Giovanni Paolo II
Bari, Italy · Completed
Istituto Europeo di Oncologia
Milan, Italy · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy · Recruiting
Istituto Oncologico Veneto
Padova, Italy · Recruiting
Ospedale Santa Maria delle Croci
Ravenna, Italy · Recruiting
Istituto Nazionale Tumori Regina Elena
Rome, Italy · Recruiting
Kanagawa Cancer Center
Kanagawa, Japan · Recruiting
Okayama University Hospital
Okayama, Japan · Recruiting
Kindai University Hospital
Osaka, Japan · Recruiting
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.